ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Gilead Sciences has agreed to acquire CV Therapeutics for $20 per share in cash, an offer that trumps the unsolicited bid of $16 per share made late last year by Japanese drugmaker Astellas Pharma. CV's board unanimously approved the Gilead deal, which is valued at approximately $1.4 billion. CV develops small-molecule drugs for cardiovascular disease. Its approved products include Ranexa, a treatment for chronic angina. Gilead, which mostly markets HIV treatments, says CV strengthens its growing cardiovascular portfolio.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X